Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Prostate Cancer

Free Subscription 24.06.2019 3 AJR Am J Roentgenol 1 Am J Pathol 1 Anticancer Res 5 BJU Int 1 Br J Cancer 1 Br J Radiol 1 Cancer Res 1 Eur J Radiol 4 Eur Urol 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Natl Cancer Inst 6 J Urol 2 Oncology (Williston Park) 4 Prostate 1 Ther Adv Urol 1 Urology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJR Am J Roentgenol

1. BAJGIRAN AM, Mirak SA, Sung K, Sisk AE, et al
   Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI.
   AJR Am J Roentgenol. 2019 Jun 19:1-9. doi: 10.2214/AJR.19.21365.
   PubMed     Text format     Abstract available
   
   
2. HUANG G, Lebovic G, Vlachou PA
   Diagnostic Value of CT in Detecting Peripheral Zone Prostate Cancer.
   AJR Am J Roentgenol. 2019 Jun 19:1-5. doi: 10.2214/AJR.18.21013.
   PubMed     Text format     Abstract available
   
   
3. SAVIR-BARUCH B, Lovrec P, Solanki AA, Adams WH, et al
   Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
   AJR Am J Roentgenol. 2019 Jun 19:1-8. doi: 10.2214/AJR.19.21153.
   PubMed     Text format     Abstract available
   
   

   
   Am J Pathol

4. DANKNER M, Ouellet V, Communal L, Schmitt E, et al
   CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis.
   Am J Pathol. 2019 Jun 11. pii: S0002-9440(18)31099.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

5. HU M, Tang Y, Long G, Zhang D, et al
   Primary Extracranial Meningioma of Mastoid in a Patient With History of Skin Squamous Cell Carcinoma, Lung Adenocarcinoma and Prostatic Carcinoma.
   Anticancer Res. 2019;39:3197-3201.
   PubMed     Text format     Abstract available
   
   

   
   BJU Int

6. WATSON RW, Taltsh O
   Transcriptomic signatures for tertiary pattern 5 in prostate cancer.
   BJU Int. 2019;124:4-5.
   PubMed     Text format    
   
   
7. DASGUPTA P, Davis J, Hughes S
   NICE guidelines on prostate cancer 2019.
   BJU Int. 2019;124:1.
   PubMed     Text format    
   
   
8. MEYER AR, Rowe SP, Gorin MA
   Preoperative PSMA-targeted PET imaging: more than just a tool for prostate cancer staging?
   BJU Int. 2019;124:2-3.
   PubMed     Text format    
   
   
9. REZAEE ME, Goddard B, Sverrisson EF, Seigne JD, et al
   Dr. Google: Trends in Online Interest in Prostate Cancer Screening, Diagnosis and Treatment.
   BJU Int. 2019 Jun 17. doi: 10.1111/bju.14846.
   PubMed     Text format     Abstract available
   
   
10. 
    NICE Guidance - Prostate cancer: diagnosis and management: (c) NICE (2019) Prostate cancer: diagnosis and management.
    BJU Int. 2019;124:9-26.
    PubMed     Text format    
    
    

    
    Br J Cancer

11. JATHAL MK, Steele TM, Siddiqui S, Mooso BA, et al
    Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.
    Br J Cancer. 2019 Jun 18. pii: 10.1038/s41416-019-0496.
    PubMed     Text format     Abstract available
    
    

    
    Br J Radiol

12. ACAR E, Leblebici A, Ellidokuz BE, Basbinar Y, et al
    Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: A retrospective radiomics study.
    Br J Radiol. 2019 Jun 20:20190286. doi: 10.1259/bjr.20190286.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

13. BOWEN C, Ostrowski MC, Leone G, Gelmann EP, et al
    Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression.
    Cancer Res. 2019 Jun 18. pii: 0008-5472.CAN-18-4110.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Radiol

14. XU M, Fang M, Zou J, Yang S, et al
    Using biparametric MRI radiomics signature to differentiate between benign and malignant prostate lesions.
    Eur J Radiol. 2019;114:38-44.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

15. CAPOGROSSO P, Vertosick EA, Benfante NE, Eastham JA, et al
    Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade.
    Eur Urol. 2019;75:221-228.
    PubMed     Text format     Abstract available
    
    
16. BENOIST GE, van Oort IM, Burger DM, Koch BCP, et al
    The Combination of Enzalutamide and Opioids: A Painful Pitfall?
    Eur Urol. 2019;75:351-352.
    PubMed     Text format    
    
    
17. CLARKE N, Payne H, van der Meulen J
    Re: David W. Donnelly, Anna Gavin, Amy Downing, et al. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.018.
    Eur Urol. 2019 Jun 15. pii: S0302-2838(19)30450.
    PubMed     Text format    
    
    
18. KLOTZ L, Loblaw A, Sugar L, Moussa M, et al
    Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
    Eur Urol. 2019;75:300-309.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

19. DU Z, Hopp H, Ingles SA, Huff C, et al
    A Genome-wide Association Study of Prostate Cancer in Latinos.
    Int J Cancer. 2019 Jun 21. doi: 10.1002/ijc.32525.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

20. SPRATT DE, Michalski JM
    Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019;104:798-800.
    PubMed     Text format    
    
    

    
    J Natl Cancer Inst

21. MOMOZAWA Y, Iwasaki Y, Hirata M, Liu X, et al
    Germline pathogenic variants in 7,636 Japanese patients with prostate cancer and 12,366 controls.
    J Natl Cancer Inst. 2019 Jun 19. pii: 5520440. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Urol

22. FRASER M
    Editorial Comment.
    J Urol. 2019;202:95.
    PubMed     Text format    
    
    
23. FRIEDLANDER TW, Welty C, Anantharaman A, Schonhoft JD, et al
    Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer.
    J Urol. 2019 Jun 19:101097JU0000000000000393. doi: 10.1097/JU.0000000000000393.
    PubMed     Text format     Abstract available
    
    
24. LAVIANA AA, Hernandez A, Huang LC, Zhao Z, et al
    Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain score translate into functional outcomes?
    J Urol. 2019 Jun 19:101097JU0000000000000392. doi: 10.1097/JU.0000000000000392.
    PubMed     Text format     Abstract available
    
    
25. WALTON-DIAZ A, Madariaga-Venegas M
    Editorial Comment.
    J Urol. 2019;202:106-107.
    PubMed     Text format    
    
    
26. BRAVI CA, Tin A, Vertosick E, Mazzone E, et al
    The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study.
    J Urol. 2019;202:108-113.
    PubMed     Text format     Abstract available
    
    
27. KLEIN EA
    Editorial Comment.
    J Urol. 2019;202:101.
    PubMed     Text format    
    
    

    
    Oncology (Williston Park)

28. BHAT A, Mas SP
    Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?
    Oncology (Williston Park). 2019;33.
    PubMed     Text format    
    
    
29. MADUEKE I, Abern MR
    Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?
    Oncology (Williston Park). 2019;33.
    PubMed     Text format    
    
    

    
    Prostate

30. UGGE H, Downer MK, Carlsson J, Bowden M, et al
    Circulating inflammation markers and prostate cancer.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23842.
    PubMed     Text format     Abstract available
    
    
31. YU W, Li J, Wang Q, Wang B, et al
    Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23838.
    PubMed     Text format     Abstract available
    
    
32. PORTER LH, Lawrence MG, Wang H, Clark AK, et al
    Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23839.
    PubMed     Text format     Abstract available
    
    
33. LEE MS, Lee J, Kim YM, Lee H, et al
    The metastasis suppressor CD82/KAI1 represses the TGF-beta 1 and Wnt signalings inducing epithelial-to-mesenchymal transition linked to invasiveness of prostate cancer cells.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23837.
    PubMed     Text format     Abstract available
    
    

    
    Ther Adv Urol

34. SCHELTEMA MJ, O'Brien TJ, van den Bos W, de Bruin DM, et al
    Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences.
    Ther Adv Urol. 2019;11:1756287219852305.
    PubMed     Text format     Abstract available
    
    

    
    Urology

35. MORENO JG, Gomella LG
    Evolution of the Liquid Biopsy in Metastatic Prostate Cancer.
    Urology. 2019 Jun 14. pii: S0090-4295(19)30535.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: